
Ollin Biosciences Raises $330 Million Series B
Austin-based Ollin Biosciences has secured an oversubscribed $330 million Series B round to advance therapies for vision-threatening diseases, signaling strong investor interest in eye health innovation. The clinical-stage company disclosed






